Navigation Links
Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
Date:3/13/2009

llular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis thrombocytopenia and asthma, as well as in cancer.

This press release contains "forward-looking" statements, including statements related to the potential efficacy of R788 for the treatment of refractory or relapsed PTCL, Rigel's plans to pursue further clinical development of R788, enrollment rate in clinical trials of R788 and the timing of results thereof. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "expects" and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause Rigel's results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of clinical trials, potential problems that may arise in the clinical testing and approval process and Rigel's need for additional capital, as well as other risks detailed from time to time in Rigel's reports filed with the Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2008. Rigel does not undertake any obligation to update forward-looking statements.

    Contact: Raul Rodriguez
    Phone: 650.624.1302
    Email: invrel@rigel.com

    Media Contact: Susan C. Rogers, Alchemy Consulting, Inc.
    Phone: 650.430.3777
    Email: susan@alchemyemail.com


'/>"/>
SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
2. Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
3. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
4. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
5. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
6. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
7. Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
8. Rigels R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
9. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
10. Novexels NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs)
11. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014  RESMED INC. (NYSE: RMD ... and fiscal year ended June 30, 2014 results on Thursday, ... close. A press release with ResMed,s results will be issued ... host a webcast to discuss operating results and future outlook. ... 1:30 p.m. US Pacific Time and the live webcast of ...
(Date:7/10/2014)... Ariz. , July 10, 2014   Ventana ...  Group, today announced it has entered into an agreement ... which operates as EMD Serono in the ... , to collaborate with Merck KGaA,s biopharmaceutical division on ... for an undisclosed target using Ventana,s proprietary diagnostic assays. ...
(Date:7/10/2014)... 2014 Decision Resources Group finds that over ... Food and Drug Administration,s (FDA) approval of Vifor Fresenius ... was approved by the FDA in November 2013 for ... patients on dialysis. Other key findings from ... 2014 : , ...
Breaking Medicine Technology:ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3
... and Raleigh, N.C., Feb. 2 , 2012 ... televisions and interactive patient education solutions, today announced ... to deploy the TIGR interactive patient education system ... is a technology driven, award-winning health system with ...
... Feb. 2, 2012 Venture capital (VC) funding in ... Biotechnology and Medical Device industries, increased 21% during 2011, ... that includes data from the PricewaterhouseCoopers LLP/National Venture ... Reuters .  Venture capitalists invested a total of $7.5 ...
Cached Medicine Technology:Centra Health and TeleHealth Services Partner to Launch Enterprise Interactive Patient Education for Patient Satisfaction and Safety 2Centra Health and TeleHealth Services Partner to Launch Enterprise Interactive Patient Education for Patient Satisfaction and Safety 3Centra Health and TeleHealth Services Partner to Launch Enterprise Interactive Patient Education for Patient Satisfaction and Safety 4Centra Health and TeleHealth Services Partner to Launch Enterprise Interactive Patient Education for Patient Satisfaction and Safety 5Life Sciences Venture Funding Jumps 21% in 2011 but Quarterly Performance Falls Short, According to the MoneyTree Report 2Life Sciences Venture Funding Jumps 21% in 2011 but Quarterly Performance Falls Short, According to the MoneyTree Report 3Life Sciences Venture Funding Jumps 21% in 2011 but Quarterly Performance Falls Short, According to the MoneyTree Report 4
(Date:7/11/2014)... (PRWEB) July 11, 2014 According to ... & Application Market by Communication Technology (ZigBee, Z-Wave, Bluetooth, ... Electronics, Industrial, Automotive & Transportation, Agriculture) & Geography - ... value of Internet of Things market was worth $1029.5 ... Billion by 2020, at an estimated CAGR of 4.08% ...
(Date:7/11/2014)... are widely applied in turf and ornamentals. They enhance ... turf and ornamentals in absorption of water, nutrient uptake, ... appear healthy and strong as a result of using ... few years. The most dominating region in biostimulants markets ... share in 2013, and is estimated to grow at ...
(Date:7/11/2014)... Toledo, Ohio (PRWEB) July 11, 2014 ... (Morgenson 7/10/14) and FiercePharma (Weintraub 7/11/14), a significant number ... in blood sugar, abdominal issues and even death from ... exposed. , According to the Times report , ... events in 2013 reported by patients was almost 14% ...
(Date:7/11/2014)... 2014) Obese and overweight firefighters are not ... providers, according to new research from The University ... , National guidelines state that health care professionals ... maintaining a healthy weight. Firefighters have high rates ... cause of line-of-duty deaths in firefighters. This study ...
(Date:7/11/2014)... New York, NY (PRWEB) July 11, 2014 ... growth during the five years to 2014 on the ... Regulations of 2010 prompted farmers to dedicate a larger ... in ethanol production. More specifically, the regulations required the ... Similarly, rapidly expanding biofuel production in the United States ...
Breaking Medicine News(10 mins):Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:Acthar’s Deadly Adverse Events Revealed 2Health News:Acthar’s Deadly Adverse Events Revealed 3Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 2Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 3
... Lower-Than-Expected Patient Volumes Seen in Houston Physician-Owned ... Tenn., March 23 HealthLeaders-InterStudy, a leading ... that while Texas laws favoring physicians have ... to compete directly with health systems, these ...
... are turning to webLAB to save time and money by ordering ... announced that consumers can now store, track and trend their webLAB ... open, Web-based platform designed to empower consumers by putting them in ... ...
... The National Small Business Association today launched a ... release of new survey data on the small-business community ... A long-time supporter of Cover the Uninsured Week, NSBA ... highlighting the need to reform the U.S. health care ...
... news that we have been waiting on for the past ... Sinus Dynamics.WESTLAKE VILLAGE, Calif., March 23 Most ENTs and ... it would be better to have a clinical study done ... sinuses. Now this fantastic news and clinical study proves the ...
... as the senior vice president for chapter operations for the American ... from 2005-2008, Gilbert was responsible for eight service areas and 760 ... managing a budget of $900 million and directing the administration of ... ...
... March 22 Telecare Corporation has appointed Pat Doyle ... new position, Doyle will focus on expanding Telecare,s 40 ... psychiatric care services. Prior to joining Telecare, he ... also spent 13 years as Senior Vice President of ...
Cached Medicine News:Health News:In Texas, Favorable Regulations for Physicians May Backfire in Light of Market Downturn 2Health News:PWN Announces That Consumers Can Now Store webLAB Test Results In Their Microsoft HealthVault Account 2Health News:PWN Announces That Consumers Can Now Store webLAB Test Results In Their Microsoft HealthVault Account 3Health News:NSBA Unveils Health Care Initiative and New Data 2Health News:New Clinical Study News for Treatment of Sinusitis, Sinus Infection and Allergy Sufferers Now Have a New Effective Form of Relief through Sinus Dynamics 2Health News:Jane H. Gilbert Appointed President and Chief Executive Officer of The ALS Association 2Health News:Jane H. Gilbert Appointed President and Chief Executive Officer of The ALS Association 3
The MACS VA_500 (variable atmosphere) is primarily for the study and isolation of microaerophilic organisms,including Campylobacter spp,Helicobacter pylori and other similarly fastdious organisms....
Lose the variability of anaerobic jars and step into the 21st century with the anaerobic workstation that provides the answer to the common problems associated with anaerobic microbiology....
... is the most versatile orthopedic/trauma ... designed for both lower body ... an integrated shoulder attachment. The ... operating table for your most ...
... With MARS, the operating theatre is ready for ... surgical fields. Its modern design allows a quick, ... The individual components are connected securely and sturdily ... system. And if there should ever be a ...
Medicine Products: